Log In
Friday 25th May 2018

Obesity drug being withdrawn

22nd January 2010

The Medicines and Healthcare Products Regulatory Agency has told doctors to stop prescribing sibutramine amid fears it increases the risk of heart attacks and strokes.

The leading obesity drug works by altering chemical messages to the brain which control cravings for food and has been used by 86,000 people in the past year. The MHRA acted after a review by the European Medicines Agency (EMA) recommended suspending its licence in Europe, though the decision still has to be formally ratified by the European Commission.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018